Back

Immorta Bio joins 2026–27 Life Sciences cohort at NYU Stern’s Endless Frontier Labs

Verifying
  • Immorta Bio joined NYU Stern’s 2026–27 Life Sciences cohort at Endless Frontier Labs.
  • The nine-month program supports the company’s transition from preclinical development toward clinical execution.
  • Immorta Bio is advancing SenoMune™ and StemCellRevivify™ therapeutic platforms.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.